$AAPG News

Reported Sunday, Ascentage Pharma's Olverembatinib And Lisaftoclax Demonstrate Strong Clinical Data Across Chronic Myeloid Leukemia, Ph+ ALL And CLL/SLL In Seventeen Updates At EHA2026 Congress

B. Riley Securities Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $45

A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness

Ascentage Pharma (AAPG) Reports Phase 1b Olverembatinib Data

Ascentage Highlights Tumor Response Data in Pediatric Cancer Study

Ascentage Highlights Leukemia Treatment Data, Expands Global Development Efforts

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Global Growth Companies Insiders Favor With Up To 40% Earnings Growth

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Reported Sunday, Ascentage Pharma Presents Preclinical Data At AACR 2026 Supporting Olverembatinib Combinations In Endometrial Carcinoma And Mantle Cell Lymphoma Alongside APG-2449 And APG-5918

Reported Sunday, Ascentage Pharma Presents Preclinical Data At AACR 2026 Supporting Olverembatinib Combinations In Endometrial Carcinoma And Mantle Cell Lymphoma Alongside APG-2449 And APG-5918

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target

Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates